Merck projected it could let go of about 6,000 employees as part of a multiyear process, affecting around 8% of its global workforce, as part of its recently announced cost-cutting initiative.
All entries for: Antiviral
August 4, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 1, 2025
Moderna
Layoffs
Cambridge, MA
1,001-5,000 employees
Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company,” CEO Stéphane Bancel told employees in a note July 31.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
July 30, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
During the company’s second quarter earnings report, Merck CEO Rob Davis said that the company was undergoing a $3 billion cut in spending, spread across administrative, sales and research and development roles. The savings amount to about $1.7 billion annually, hoping to hit the $3 billion mark by 2027.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 21, 2025
GSK - Cambridge
Layoffs
Cambridge, MA
50,001+ employees
GSK is letting go of 150 employees in Cambridge, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Endpoints News reported that the London-based company plans to move manufacturing of its pneumococcal vaccine asset that uses its multiple antigen presenting system (MAPS) technology from Cambridge to Marietta, Pennsylvania.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
June 16, 2025
Gilead Sciences - Oceanside
Layoffs
Oceanside, CA
10,001-50,000 employees
Gilead Sciences cut 36 employees in Oceanside, California, effective Aug. 15, according to a Worker Adjustment and Retraining Notification notice. The location supports clinical manufacturing and process development for the Foster City, California–based pharma and subsidiary Kite Pharma.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 7, 2025
Gilead Sciences
Negative Outlook
Foster City, CA
10,001-50,000 employees
While the full impact of the IRA on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the IRA will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 2, 2025
Merck
Negative Outlook
Rahway, NJ
10,001-50,000 employees
Pursuant to the IRA’s Program, a government price was set for Januvia, which will become effective on January 1, 2026. In January 2025, the U.S. Department of HHS, through the CMS, announced that Janumet and Janumet XR would be in included in the second year of the IRA’s Program, with government price setting to become effective on January 1, 2027. The Company has sued the U.S. government regarding the IRA’s Program. Additionally, increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company’s ability to identify inappropriate discounts are having a negative impact on Company performance. Furthermore, the Executive Branch and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first three months of 2025 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect sales and profits.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
April 2, 2025
Gilead Sciences
Layoffs
Foster City, CA
10,001-50,000 employees
Gilead is trimming its California workforce by 149, according to a WARN Notice posted last week. The layoffs will take effect on May 27 and will affect scientific and technical services at the pharma’s site in Foster City.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
March 20, 2025
TC BioPharm
Layoffs
Motherwell, United Kingdom
51-200 employees
TC BioPharm is letting go around 20 employees, or approximately half of its headcount, in line with its push to become a “leaner and more agile” company with a more decentralized model. The workforce reduction is part of a larger shift within the company toward a CDMO model, allowing it to respond to larger production demands for future trials, as well as giving it the opportunity to look for alternative manufacturing facilities that can incorporate more advanced technologies. The layoffs will mostly affect employees in the company’s production and quality units and will be “substantially complete” by the end of the second quarter.
Disease Area: Antiviral, Infectious Diseases, Multiple, Oncology
Drug Type: Biologic
March 6, 2025
Atea Pharmaceuticals
Layoffs
Bston, MA
51-200 employees
25% reduction in workforce.
Disease Area: Antiviral, Rare Diseases
Drug Type: Biologic, Small Molecule